We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Clinical Data announced that its PGxHealth Division has completed enrollment in a pivotal Phase III study of Vilazodone, in development for the treatment of depression.
Study results presented at the 17th European Congress of Clinical Microbiology and Infectious Diseases show that the antibiotic telavancin and the antifungal micafungin both have the potential to meet a significant unmet need in the fight against serious hospital-acquired infections, according to Astellas Pharma.
The European Commission has approved Xeloda in combination with platinum-based chemotherapy for first-line use in patients with advanced stomach cancer, Roche announced.
The FDA announced it has approved Ceprotin, the first biologic treatment for patients with a rare genetic defect that can cause a potentially life-threatening blood clotting disorder.
Merck announced that the FDA has approved Janumet, a tablet combining a Januvia, a dipeptidyl peptidase-4 (DPP-4) inhibitor, and metformin for the treatment of Type 2 diabetes.
Abbott announced it has submitted a supplemental biologics license application to the FDA and a Type II variation to the European Medicines Agency seeking approval to market Humira as a treatment for moderate to severe chronic plaque psoriasis.